MedPath

Flurandrenolide

Flurandrenolide Lotion USP, 0.05%

Approved
Approval ID

2718df54-7dc1-4ebc-8258-607bedcf5813

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Aug 17, 2023

Manufacturers
FDA

Bryant Ranch Prepack

DUNS: 171714327

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Flurandrenolide

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code72162-1439
Application NumberANDA207133
Product Classification
M
Marketing Category
C73584
G
Generic Name
Flurandrenolide
Product Specifications
Route of AdministrationTOPICAL
Effective DateAugust 17, 2023
FDA Product Classification

INGREDIENTS (10)

FLURANDRENOLIDEActive
Quantity: 0.5 mg in 1 mL
Code: 8EUL29XUQT
Classification: ACTIB
STEARIC ACIDInactive
Code: 4ELV7Z65AP
Classification: IACT
GLYCERINInactive
Code: PDC6A3C0OX
Classification: IACT
CETYL ALCOHOLInactive
Code: 936JST6JCN
Classification: IACT
MINERAL OILInactive
Code: T5L8T28FGP
Classification: IACT
GLYCERYL MONOSTEARATEInactive
Code: 230OU9XXE4
Classification: IACT
POLYOXYL 40 STEARATEInactive
Code: 13A4J4NH9I
Classification: IACT
BENZYL ALCOHOLInactive
Code: LKG8494WBH
Classification: IACT
MENTHOL, UNSPECIFIED FORMInactive
Code: L7T10EIP3A
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT

Drug Labeling Information

CLINICAL PHARMACOLOGY SECTION

LOINC: 34090-1Updated: 9/26/2016

CLINICAL PHARMACOLOGY

Flurandrenolide Lotion USP, 0.05% is primarily effective because of its anti- inflammatory, antipruritic, and vasoconstrictive actions.

The mechanism of the anti-inflammatory effect of topical corticosteroids is not completely understood. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Corticosteroids with anti-inflammatory activity may stabilize cellular and lysosomal membranes. There is also the suggestion that the effect on the membranes of lysosomes prevents the release of proteolytic enzymes and, thus, plays a part in reducing inflammation.

Evaporation of water from the lotion vehicle produces a cooling effect, which is often desirable in the treatment of acutely inflamed or weeping lesions.

Pharmacokinetics -

The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to those of systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. They are metabolized primarily in the liver and then excreted in the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Flurandrenolide - FDA Drug Approval Details